Cargando…
Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity
OBJECTIVE: SLE is a common multisystem autoimmune disease with chronic inflammation. Many efficacy evaluation indicators of randomised clinical trials (RCTs) for SLE have been proposed but the comparability remains unknown. We aim to explore the preference and comparability of indicators reporting r...
Autores principales: | Tian, Jingru, Kang, Shuntong, Zhang, Dingyao, Huang, Yaqing, Yao, Xu, Zhao, Ming, Lu, Qianjin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565300/ https://www.ncbi.nlm.nih.gov/pubmed/37798046 http://dx.doi.org/10.1136/lupus-2023-000942 |
Ejemplares similares
-
Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study
por: Tian, Jingru, et al.
Publicado: (2023) -
Coping with systemic lupus erythematosus in patients’ words
por: Cornet, Alain, et al.
Publicado: (2022) -
Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022) -
Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus
por: Jallouli, M, et al.
Publicado: (2014) -
Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)